Hangzhou TianMuShan Pharmaceutical Enterprise Co (SHSE:600671) Other Current Payables: ¥27.3 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:600671 Hangzhou TianMuShan Pharmaceutical Enterprise Co Ltd SHSE:600671
51 GF Score
Price ¥19.68
GF Value ¥15.05
Valuation Significantly Overvalued
! 8 Warning Signs
View Full Analysis

What is Hangzhou TianMuShan Pharmaceutical Enterprise Co Other Current Payables?

Hangzhou TianMuShan Pharmaceutical Enterprise Co SHSE:600671 +1.81% 51 Other Current Payables is ¥27.3 Mil as of Mar. 2026. GuruFocus rates SHSE:600671 with a GF Score™ of 51/100 and a GF Value™ of ¥15.05 (Significantly Overvalued). The stock has 8 warning signs investors should review.

Hangzhou TianMuShan Pharmaceutical Enterprise Co's Other Current Payables for the quarter that ended in Mar. 2026 was ¥27.3 Mil.

Hangzhou TianMuShan Pharmaceutical Enterprise Co's quarterly Other Current Payables increased from Sep. 2025 (¥25.0 Mil) to Dec. 2025 (¥29.8 Mil) but then declined from Dec. 2025 (¥29.8 Mil) to Mar. 2026 (¥27.3 Mil).

Hangzhou TianMuShan Pharmaceutical Enterprise Co's annual Other Current Payables declined from Dec. 2023 (¥53.0 Mil) to Dec. 2024 (¥38.9 Mil) and declined from Dec. 2024 (¥38.9 Mil) to Dec. 2025 (¥29.8 Mil).

Hangzhou TianMuShan Pharmaceutical Enterprise Co Other Current Payables Related Terms

Hangzhou TianMuShan Pharmaceutical Enterprise Co Other Current Payables Historical Data

* Premium members only.

The historical data trend for Hangzhou TianMuShan Pharmaceutical Enterprise Co's Other Current Payables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Hangzhou TianMuShan Pharmaceutical Enterprise Co Other Current Payables Chart

Hangzhou TianMuShan Pharmaceutical Enterprise Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Payables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 69.48 58.95 53.05 38.93 29.76

Hangzhou TianMuShan Pharmaceutical Enterprise Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Current Payables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 32.87 22.68 24.97 29.76 27.31
SHSE:600671
51GF Score
Hangzhou TianMuShan Pharmaceutical Enterprise Co Ltd SHSE:600671
Other Current Payables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Hangzhou TianMuShan Pharmaceutical Enterprise Co Other Current Payables Calculation

Other Current Payables is the payables owed and expected to be paid within one year or one operating cycle that not otherwise classified. It includes dividends payable and all other current payables.

Frequently Asked Questions Learn more about Other Current Payables →
What does a Other Current Payables of ¥27.3 Mil mean?
Hangzhou TianMuShan Pharmaceutical Enterprise Co (SHSE:600671) has a Other Current Payables of ¥27.3 Mil as of Mar. 2026. Other Current Payables is the payables owed and expected to be paid within one year that not otherwise classified. View historical data on Hangzhou TianMuShan Pharmaceutical Enterprise Co and its competitors.
Is Hangzhou TianMuShan Pharmaceutical Enterprise Co's Other Current Payables too high?
Hangzhou TianMuShan Pharmaceutical Enterprise Co's current Other Current Payables is ¥27.3 Mil. Overall, Hangzhou TianMuShan Pharmaceutical Enterprise Co has a GF Score™ of 51/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Hangzhou TianMuShan Pharmaceutical Enterprise Co's Other Current Payables compare to LLY and JNJ?
Hangzhou TianMuShan Pharmaceutical Enterprise Co's Other Current Payables of ¥27.3 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Payables for a Drug Manufacturers company?
A good Other Current Payables depends on the Drug Manufacturers industry context. However, Other Current Payables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Payables mean?
A high Other Current Payables can signal that a stock is expensive relative to its fundamentals. Other Current Payables is the payables owed and expected to be paid within one year that not otherwise classified. View historical data on Hangzhou TianMuShan Pharmaceutical Enterprise Co and its competitors. Hangzhou TianMuShan Pharmaceutical Enterprise Co's current Other Current Payables is ¥27.3 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hangzhou TianMuShan Pharmaceutical Enterprise Co stock overvalued right now?
Based on GuruFocus' analysis, Hangzhou TianMuShan Pharmaceutical Enterprise Co (SHSE:600671) is currently considered Significantly Overvalued. The stock's GF Value™ is ¥15.05, compared to a current price of ¥19.68 — trading 30.8% above its estimated fair value. The current Other Current Payables is ¥27.3 Mil. Hangzhou TianMuShan Pharmaceutical Enterprise Co's overall GF Score™ is 51/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Payables calculated?
Other Current Payables is calculated from a company's financial statements. For Hangzhou TianMuShan Pharmaceutical Enterprise Co (SHSE:600671), the current Other Current Payables is ¥27.3 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Hangzhou TianMuShan Pharmaceutical Enterprise Co (SHSE:600671) Overvalued in 2026?

Based on GuruFocus' analysis, Hangzhou TianMuShan Pharmaceutical Enterprise Co stock appears to be overvalued. The current stock price of ¥19.68 is trading 30.8% above its estimated GF Value™ of ¥15.05. GuruFocus considers Hangzhou TianMuShan Pharmaceutical Enterprise Co to be Significantly Overvalued.

Key valuation signals for SHSE:600671:

  • Other Current Payables: ¥27.3 Mil
  • GF Value™: ¥15.05 vs. price of ¥19.68 (30.8% above fair value)
  • GF Score™: 51/100 with 8 warning signs

No single metric tells the full story. See the SHSE:600671 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Hangzhou TianMuShan Pharmaceutical Enterprise Co Business Description

Address No.18 Shangyang Road, Jinnan Street, Lin'an District, Zhejiang Province, Hangzhou, CHN, 311200
Hangzhou TianMuShan Pharmaceutical Enterprise Co Ltd is engaged in producing proprietary Chinese medicines, biopharmaceuticals, healthy foods, medical equipment, and other medicines in China.
51GF Score

Get the complete analysis for SHSE:600671

Other Current Payables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥19.68
Price
¥15.05
GF Value